A new study, published in the Annals of Internal Medicine, says that if gay and bi men with HIV undergo routine screening for ...

People with autoimmune skin diseases had significantly better cancer survival outcomes than others. Survival benefits were ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

Incomplete immune recovery despite sustained virologic suppression in patients with HIV was associated with increased risk for incident cancer.

Lenacapavir has demonstrated enormous potential as a new HIV prevention tool with a 100 per cent efficacy rate and zero ...

Lenacapavir is a major step forward in HIV prevention. With just two injections a year, it is a simple and highly effective ...

Steve Drayton, a man living with HIV and a three-time cancer survivor, has dedicated the last 30 years of his life to ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

Updated at 3:38 p.m. ET on May 31, 2025 Solving HIV vaccination—a puzzle that scientists have been tackling for decades without success—could be like cracking the code to a safe.

There is no HIV vaccine approved by the US Food and Drug Administration. However, recently two HIV vaccine trials were conducted in the US and Africa. A study, based on those trials and published in ...

HIV causes changes to the immune system, which may result in skin irritation. An HIV rash that's itchy, reddish or dark purplish, and painful may develop.